The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Exposing the molecular heterogeneity of glycosylated biotherapeutics
Open accessPreprint — published as 10.1038/s41467-024-47693-8 · Paper page
Abstract
Glycosylated biotherapeutics are an emerging class of drugs with high molecular heterogeneity, which can affect their safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins. Here, we present a new approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment and offers insights into glycoform composition when coupled with a suitable bioinformatic strategy. We tested the approach on various biotherapeutic molecules, including Fc-fusion, VHH-fusion, and peptide-bound MHC class II complexes to demonstrate efficacy in measuring the proteoform-level diversity of biotherapeutics. Notably, we inferred the glycoform distribution for hundreds of molecular weights for the eight-times glycosylated fusion drug IL22-Fc, enabling correlations between glycoform sub-populations and the drug’s pharmacological properties. Our method is broadly applicable and provides a powerful tool to assess the molecular heterogeneity of emerging biotherapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How many human proteoforms are there?
Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., Costello, C. E., Cravatt, B. F., Fenselau, C., Garcia, B. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2576 · Cited by 907
Self-citation
Flagged first, then by citations
Research works printed but not linked: 58
- Rathore, A. S. & Winkle, H. Quality by design for biopharmaceuticals. Nat Biotechnol 27, 26–34 (2009). · DOI
- Walsh, G. Biopharmaceutical benchmarks 2018. Nat Biotechnol 36, 1136–1145 (2018). · DOI · Paper page
- Zhang, P. et al. Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Discov Today 21, 740–765 (2016). · DOI
- Yehuda, S. & Padler-Karavani, V. Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid. Front Immunol 11, 21 (2020). · DOI · Paper page
- Silsirivanit, A. Chapter Five Glycosylation markers in cancer. Adv Clin Chem 89, 189–213 (2019). · DOI
- Aebi, M., Bernasconi, R., Clerc, S. & Molinari, M. N-glycan structures: recognition and processing in the ER. Trends Biochem Sci 35, 74–82 (2010). · DOI
- Gabius, H.-J. The sugar code: Why glycans are so important. Biosystems 164, 102–111 (2018). · DOI
- Elliott, S. et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21, 414–421 (2003). · DOI
- Lowe, J. B. & Marth, J. D. Essentials of Glycobiology. in Chap. 16, Structures Common to Different Types of Glycans. (eds. A, V., R, C. & J, E.) (Cold Spring Harbor Laboratory Press, 1999).
- Mariño, K., Bones, J., Kattla, J. J. & Rudd, P. M. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 6, 713–723 (2010). · DOI
- Rathore, D. et al. The role of mass spectrometry in the characterization of biologic protein products. Expert Rev Proteomic 15, 431–449 (2018). · DOI
- Rogstad, S. et al. A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications. J Am Soc Mass Spectr 28, 786–794 (2017). · DOI
- Xiao, H., Sun, F., Suttapitugsakul, S. & Wu, R. Global and site-specific analysis of protein glycosylation in complex biological systems with Mass Spectrometry. Mass Spectrom. Rev. 38, 356–379 (2019). · DOI
- Shen, J. et al. StrucGP: de novo structural sequencing of site-specific N-glycan on glycoproteins using a modularization strategy. Nat Methods 18, 921–929 (2021). · DOI
- Geyer, H. & Geyer, R. Strategies for analysis of glycoprotein glycosylation. Biochimica Et Biophysica Acta Bba - Proteins Proteom 1764, 1853–1869 (2006). · DOI
- Wang, T. et al. Application of a Quantitative LC–MS Multiattribute Method for Monitoring Site-Specific Glycan Heterogeneity on a Monoclonal Antibody Containing Two NLinked Glycosylation Sites. Anal Chem 89, 3562–3567 (2017). · DOI
- Sun, S. et al. Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. Nat Biotechnol 34, 84–88 (2016). · DOI
- Yang, Y. et al. Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity. Nat Commun 7, 13397 (2016). · DOI · Paper page
- Wohlschlager, T. et al. Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals. Nat Commun 9, 1713 (2018). · DOI
- Solá, R. J. & Griebenow, K. Glycosylation of Therapeutic Proteins. Biodrugs 24, 9–21 (2010). · DOI
- Stephenson, J. L., Berkel, G. J. V. & McLuckey, S. A. Ion-ion proton transfer reactions of bio-ions involving noncovalent interactions: Holomyoglobin. J Am Soc Mass Spectr 8, 637–644 (1997). · DOI · Paper page
- Stephenson, J. L. & McLuckey, S. A. Ion/Ion Proton Transfer Reactions for Protein Mixture Analysis. Anal Chem 68, 4026–4032 (1996). · DOI · Paper page
- Anderson, L. C. et al. Protein derivatization and sequential ion/ion reactions to enhance sequence coverage produced by electron transfer dissociation mass spectrometry. Int J Mass Spectrom 377, 617–624 (2015). · DOI · Paper page
- Coon, J. J. et al. Protein identification using sequential ion/ion reactions and tandem mass spectrometry. Proc National Acad Sci 102, 9463–9468 (2005). · DOI · Paper page
- Huguet, R. et al. Proton Transfer Charge Reduction Enables High-Throughput Top-Down Analysis of Large Proteoforms. Anal Chem 91, 15732–15739 (2019). · DOI · Paper page
- Belov, M. E. et al. From Protein Complexes to Subunit Backbone Fragments: A Multi-stage Approach to Native Mass Spectrometry. Anal Chem 85, 11163–11173 (2013). · DOI · Paper page
- Kafader, J. O. et al. Native vs Denatured: An in Depth Investigation of Charge State and Isotope Distributions. J Am Soc Mass Spectr 31, 574–581 (2020). · DOI · Paper page
- Cai, X. et al. PulseDIA: Data-Independent Acquisition Mass Spectrometry Using Multi-Injection Pulsed Gas-Phase Fractionation. J Proteome Res 20, 279–288 (2021). · DOI
- Smith, L. M. et al. Proteoform: a single term describing protein complexity. Nat Methods 10, 186–187 (2013). · DOI · Paper page
- Leney, A. C. & Heck, A. J. R. Native Mass Spectrometry: What is in the Name? J Am Soc Mass Spectr 28, 5–13 (2017). · DOI · Paper page
- Čaval, T., Tian, W., Yang, Z., Clausen, H. & Heck, A. J. R. Direct quality control of glycoengineered erythropoietin variants. Nat Commun 9, 3342 (2018). · DOI
- Marty, M. T. et al. Bayesian Deconvolution of Mass and Ion Mobility Spectra: From Binary Interactions to Polydisperse Ensembles. Anal Chem 87, 4370–4376 (2015). · DOI · Paper page
- Muthu, M. et al. Insights into Bioinformatic Applications for Glycosylation: Instigating an Awakening towards Applying Glycoinformatic Resources for Cancer Diagnosis and Therapy. Int J Mol Sci 21, 9336 (2020). · DOI
- Rojas-Macias, M. A. et al. Towards a standardized bioinformatics infrastructure for N- and O-glycomics. Nat Commun 10, 3275 (2019). · DOI
- Rogstad, S. et al. Multi-Attribute Method for Quality Control of Therapeutic Proteins. Anal Chem 91, 14170–14177 (2019). · DOI · Paper page
- Rogers, R. S. et al. Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. Mabs 7, 881–890 (2015). · DOI · Paper page
- Rademacher, C. & Paulson, J. C. Glycan Fingerprints: Calculating Diversity in Glycan Libraries. Acs Chem Biol 7, 829–834 (2012). · DOI
- FDA. Guidance for Industry: Q11 Development and Manufacture of Drug Substances. Preprint at https://www.fda.gov/files/drugs/published/Q11-Development-and-Manufacture-of-Drug-Substances.pdf (2012).
- Gabius, H. et al. What is the Sugar Code? Chembiochem 23, e202100327 (2022).
- Atwell, S., Ridgway, J. B. B., Wells, J. A. & Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library11Edited by P.E.Wright. J Mol Biol 270, 26–35 (1997). · DOI
- Bannas, P., Hambach, J. & Koch-Nolte, F. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics. Front Immunol 8, 1603 (2017). · DOI · Paper page
- Yang, Y., Barendregt, A., Kamerling, J. P. & Heck, A. J. R. Analyzing Protein Micro-Heterogeneity in Chicken Ovalbumin by High-Resolution Native Mass Spectrometry Exposes Qualitatively and Semi-Quantitatively 59 Proteoforms. Anal Chem 85, 12037–12045 (2013). · DOI
- Schachner, L. F. et al. High-Throughput, Quantitative Analysis of Peptide-Exchanged MHCI Complexes by Native Mass Spectrometry. Anal Chem (2022) doi:10.1021/acs.analchem.2c02423. · DOI
- Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017). · DOI · Paper page
- Ryan, S. O. & Cobb, B. A. Roles for major histocompatibility complex glycosylation in immune function. Semin Immunopathol 34, 425–441 (2012). · DOI
- Rothenberg, M. E. et al. Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): A Potential Therapy for Epithelial Injury. Clin Pharmacol Ther 105, 177–189 (2019). · DOI
- Stefanich, E. G. et al. Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases. Biochem Pharmacol 152, 224–235 (2018). · DOI
- Gao, B. & Xiang, X. Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cell Mol Immunol 16, 666–667 (2019). · DOI
- Berndsen, Z. T. et al. Visualization of the HIV-1 Env glycan shield across scales. Proc National Acad Sci 117, 28014–28025 (2020). · DOI · Paper page
- Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat Rev Immunol 7, 255–266 (2007). · DOI
- Kightlinger, W. et al. Design of glycosylation sites by rapid synthesis and analysis of glycosyltransferases. Nat Chem Biol 14, 627–635 (2018). · DOI
- Meuris, L. et al. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat Biotechnol 32, 485–489 (2014). · DOI · Paper page
- Hershewe, J. M. et al. Improving cell-free glycoprotein synthesis by characterizing and enriching native membrane vesicles. Nat Commun 12, 2363 (2021). · DOI
- Jaroentomeechai, T. et al. Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery. Nat Commun 9, 2686 (2018). · DOI
- Schachner, L. F. et al. Decoding the protein composition of whole nucleosomes with Nuc-MS. Nat Methods 18, 303–308 (2021). · DOI
- Ruthenburg, A. J. et al. Recognition of a Mononucleosomal Histone Modification Pattern by BPTF via Multivalent Interactions. Cell 145, 692–706 (2011). · DOI
- Casalino, L. et al. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. Acs Central Sci 6, 1722–1734 (2020). · DOI
- Sperinde, G. et al. Challenges with development of a pharmacokinetics assay to measure a variably glycosylated fusion protein. Bioanalysis 14, 7–18 (2021). · DOI
Metadata
- Authors
- Schachner, L., Mullen, C., Phung, W., Hinkle, J., Beardsley, M. I., Bentley, T., Day, P., Tsai, C., Sukumaran, S., Baginski, T., DiCara, D., Agard, N., Masureel, M., Gober, J., ElSohly, A., Syka, J., Huguet, R., Marty, M., & Sandoval, W.
- Affiliations
- Genentech (US)
- Thermo Fisher Scientific (United States) (US)
- University of Arizona (US)
- Corresponding author
- Sandoval, Wendy
- ORCID
- Venue
- Nature Communications
- Published
- 2023-05-25
- Volume
- 15
- Issue
- 1
- Pages
- 3259-3259
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11021452
- OpenAlex
- W4394845195
- Cited by
- 37
- References
- 1
- Citations by year
- 2026: 19 · 2025: 12 · 2024: 6
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Foundation (1845230)
- Genentech
- Division of Chemistry (CHE-1845230)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- molecular heterogeneity, glycoproteins, gas-phase fractionation, proteoforms, Fc fusion protein, glycan composition
- MeSH terms
- Glycoproteins, Glycosylation, Polysaccharides, Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review